viewOrganovo Holdings Inc.

Organovo reports smaller loss and sharp fall in revenue

The net loss for the quarter was lower compared to last year but revenues slid

Organovo is a biotech company that develops 3D bioprinted tissues

Organovo Holdings Inc (NASDAQ:ONVO) said on Thursday it posted a net loss which was smaller than last year but revenue declined sharply because of a fall in research income.

The company said its net loss for the quarter was at US$7.4mln, a US$2.7mln improvement over the year ago level. The reason for the smaller loss is due to lower employee and lab suuply costs. Total revenue was US$700,000, from US$990,000 in the same period last year.

READ: Shares of Organovo fall after it narrows fiscal 2018 guidance

Revenue was driven down by lower income from liver tissue modeling research services.

Organovo is a biotechnology company that pioneers in the development of 3D bioprinted tissues aimed at treating a variety of liver diseases. The company is based in San Diego, California.

Contact Rene Pastor at [email protected]


Quick facts: Organovo Holdings Inc.

Price: 0.7054 USD

Market: NASDAQ
Market Cap: $92.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Auryn Resources spins our Peruvian assets creating a new company called Fury...

Auryn Resources (TSE: AUG- NYSEAMERICAN: AUG) Executive Chairman Ivan Bebek and new company Fury Gold Mines CEO Mike Timmins joined Steve Darling from Proactive Vancouver with news Auryn is creating a new gold-focused exploration and development company called Fury Gold Mines. Bebek discusses...

2 hours, 35 minutes ago

2 min read